Phyteau
Phyteau is a private, early-stage biotechnology company founded in 2017 that is developing a new class of therapeutics for diabetes, obesity, weight-loss, and metabolism, serving the metabolic disease patient population through future pharmaceutical commercialization.
- Company typePrivate
- Founded2017
- HeadquartersLewes, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
Phyteau firmographics
Firmographics- Name
- Phyteau
- Website
- https://phyteau.co
- Company type
- Private
- Founded year
- 2017
- Headcount range
- 1–10 employees
- Short description
- Phyteau is a private, early-stage biotechnology company founded in 2017 that is developing a new class of therapeutics for diabetes, obesity, weight-loss, and metabolism, serving the metabolic disease patient population through future pharmaceutical commercialization.
- Ownership category
- akta.pro rank
Phyteau industry classification
Industry- Product category
- Metabolic Disease Therapeutics
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE)
- akta.pro secondary industries
- Translational Medicine & Biomarkers (HLAIALAF), Therapeutic Peptides & Protein/Peptide Biologics (HLAAAAAH)
Keywords
Where Phyteau is headquartered
LocationHeadquarters
- HQ city
- Lewes
- HQ country
- United States
- HQ region
- North America
Markets served
Phyteau business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations
Phyteau product offering
Product offeringCore offering
Phyteau is developing a new class of therapeutics targeting diabetes, obesity, weight-loss, and broader metabolic disorders. The company operates as a preclinical-stage biopharmaceutical research firm advancing novel therapeutic candidates in the metabolic disease space. Its activities center on early-stage drug discovery and development rather than currently marketed products.
Differentiator
Problem solved
Functional benefit
Companies that use Phyteau
Customer profileIdeal customer profiles1 record
Phyteau technology and API
TechnologyAPI detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Phyteau partnerships and signals
Strategic signalRecent moves2 records
Expansion highlights1 record
Phyteau competitors and assessment
Company assessmentDirect peers
- Zealand Pharma: Denmark-based clinical-stage biotech developing peptide therapeutics for metabolic diseases, including obesity and diabetes. Highly comparable to Phyteau given overlapping indication focus and peptide-modality approach in cardiometabolic disease.
- Structure Therapeutics: Clinical-stage biotech developing oral small-molecule GLP-1 agonists for obesity and diabetes. Comparable as a small, focused metabolic-disease therapeutics company targeting the same endocrinology indications.
- vTv Therapeutics: Clinical-stage biopharma developing small-molecule therapeutics for type 1 and type 2 diabetes and related metabolic disorders. Comparable given the diabetes/metabolism focus and small-cap biotech profile.
- Carmot Therapeutics: Preclinical-to-clinical biotech developing peptide therapeutics for metabolic disease (acquired by Roche in 2024). Comparable as a small, focused metabolic-disease peptide therapeutics company recently validated by a major pharma acquisition.
- Inversago Pharma: Clinical-stage biotech developing CB1 receptor-based therapies for obesity and metabolic disorders (acquired by Novo Nordisk in 2023). Comparable as a small-cap obesity-focused biotech whose strategic exit validates the M&A appetite in this space.
Emerging players
- Metsera: Recently launched clinical-stage biotech developing next-generation obesity therapeutics. Comparable as an emerging capital-backed obesity drug developer entering the same competitive landscape as Phyteau.
Broad incumbents
- Eli Lilly: Global pharmaceutical leader with tirzepatide (Mounjaro/Zepbound) dominating the obesity and diabetes market. Comparable as the standard-setter in cardiometabolic therapeutics whose clinical bar Phyteau must meet or differentiate against.
- Novo Nordisk: Global leader in diabetes care and the originator of semaglutide (Ozempic/Wegovy). Comparable as the incumbent defining efficacy, safety, and commercial benchmarks in Phyteau's target indications.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat2 records
Key risks6 records
Key highlights5 records
Customer concentration
Phyteau social profiles
Digital presencePhyteau financial estimates
Financial estimateRevenue estimate
Valuation estimate
Phyteau leadership team
Management profileNumber of profiles
Profiles3 records
Phyteau funding detail
Funding detailFunding overview
Funding rounds1 record
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Phyteau M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Phyteau
What does Phyteau do?
Phyteau is developing a new class of therapeutics targeting diabetes, obesity, weight-loss, and broader metabolic disorders. The company operates as a preclinical-stage biopharmaceutical research firm advancing novel therapeutic candidates in the metabolic disease space. Its activities center on early-stage drug discovery and development rather than currently marketed products.
When was Phyteau founded?
Phyteau was founded in 2017. It employs 1 to 10 people.
Where is Phyteau based?
Phyteau is headquartered in Lewes, United States, in the North America region.
Who are Phyteau's main competitors?
Direct peers on record are Zealand Pharma, Structure Therapeutics, vTv Therapeutics, Carmot Therapeutics and Inversago Pharma. Metsera is listed as an emerging player. Broad incumbents are Eli Lilly and Novo Nordisk.
Does Phyteau have an API?
No public API is recorded for Phyteau.
What industry is Phyteau in?
Phyteau's product category is Metabolic Disease Therapeutics. Its primary akta.pro industry code is HLAIAAAE, Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity), with a secondary code of HLAIALAF, Translational Medicine & Biomarkers. Its NAICS code is 541714 and its SIC code is 2834.